TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized-Withdrawal Phase 3 Study Evaluation the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Brief Summary: Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with moderate to severe itching associated with end-stage renal disease and hemodialysis, and perform a population PK analysis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Senna; Type: ACTIVE_COMPARATOR; Interventions: Drug: Senna | Intervention Type: DRUG; Name: Senna; Assigned to Arm(s): Senna | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 2.5 µg | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nalfurafine HCl 5.0 µg | Intervention Type: DRUG; Name: Nalfurafine HCl 2.5 µg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nalfurafine HCl 5.0 µg; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin 75mg daily for 12 weeks | Arm Label: fexofenadine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fexofenadine 60 mg daily for 12 weeks | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin 75mg daily for 12 weeks; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: fexofenadine 60 mg daily for 12 weeks; Assigned to Arm(s): fexofenadine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: cromolyn sodium | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: cromolyn sodium; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial
Brief Summary: The aim of this study is to determine the feasibility of conducting a trial to examine the efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention of progression of PNALD in infants with Intestinal Failure/Short Bowel Syndrome (SBS) and early liver dysfunction.


Options:
A: Arm Label: Olive oil lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: ClinOleic | Arm Label: MCT/LCT lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: Lipofundin | Arm Label: LCT lipid emulsion; Type: EXPERIMENTAL; Interventions: Drug: Intralipid | Intervention Type: DRUG; Name: ClinOleic; Assigned to Arm(s): Olive oil lipid emulsion | Intervention Type: DRUG; Name: Lipofundin; Assigned to Arm(s): MCT/LCT lipid emulsion | Intervention Type: DRUG; Name: Intralipid; Assigned to Arm(s): LCT lipid emulsion
B: Arm Label: Smoflipid; Type: EXPERIMENTAL; Interventions: Drug: SMOFLIPID | Arm Label: Intralipid; Type: ACTIVE_COMPARATOR; Interventions: Drug: INTRALIPID | Intervention Type: DRUG; Name: SMOFLIPID; Assigned to Arm(s): Smoflipid | Intervention Type: DRUG; Name: INTRALIPID; Assigned to Arm(s): Intralipid
C: Arm Label: SMOFlipid; Type: EXPERIMENTAL; Interventions: Other: SMOFlipid | Arm Label: Lipofundin; Type: OTHER; Interventions: Other: Lipofundin | Intervention Type: OTHER; Name: SMOFlipid; Assigned to Arm(s): SMOFlipid | Intervention Type: OTHER; Name: Lipofundin; Assigned to Arm(s): Lipofundin
D: Arm Label: 1) Intralipid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intralipid 20% | Arm Label: 2) SMOFlipid; Type: EXPERIMENTAL; Interventions: Drug: SMOFlipid 20% | Intervention Type: DRUG; Name: Intralipid 20%; Assigned to Arm(s): 1) Intralipid | Intervention Type: DRUG; Name: SMOFlipid 20%; Assigned to Arm(s): 2) SMOFlipid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Deep Dive Randomized Control Trial
Brief Summary: Compare two care management support program models on medical costs and utilization.


Options:
A: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group
B: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: evidence based decision aid, Behavioral: Possible reimbursement 4th IVF/ICSI cycle when necessary | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: evidence based decision aid; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Possible reimbursement 4th IVF/ICSI cycle when necessary; Assigned to Arm(s): 1
D: Intervention Type: DEVICE; Name: Heart-to-Heart Decision Aid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Deep Dive Randomized Control Trial
Brief Summary: Compare two care management support program models on medical costs and utilization.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: SMS and Internet; Type: EXPERIMENTAL; Interventions: Behavioral: MD2ME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MD2ME; Assigned to Arm(s): SMS and Internet
C: Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): N/A
D: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Deep Dive Randomized Control Trial
Brief Summary: Compare two care management support program models on medical costs and utilization.


Options:
A: Arm Label: Health coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching
B: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Plant Stanol Ester-Containing Spread Based on Extra Virgin Olive Oil on Estimated Cardiovascular Risk, and Lipid-Inflammatory-Haemostatic Factors in Comparison to Mediterranean Diet: A Randomized, Placebo-Controlled Trial.
Brief Summary: Since it is very difficult to have the real thing (Mediterranean diet) we need to find an alternative to reduce cardiovascular disease (CVD) risk in subjects with moderate hypercholesterolaemia (a major CVD risk factor) living in western countries. Therefore, this proposed study is designed to assess if giving olive oil supplements, with or without stanol ester, is equivalent to following a Mediterranean diet. Furthermore, the stanol-olive oil combination may prove to be superior to olive oil alone.


Options:
A: Arm Label: Experimental diet; Type: EXPERIMENTAL; Interventions: Other: Experimental diet | Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control diet | Intervention Type: OTHER; Name: Experimental diet; Assigned to Arm(s): Experimental diet | Intervention Type: OTHER; Name: Control diet; Assigned to Arm(s): Control diet
B: Arm Label: Stanol ester; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Stanol ester spread | Arm Label: Placebo spread; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo spread | Arm Label: Mediterranean diet group; Type: OTHER; Interventions: Dietary Supplement: Mediterranean Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Stanol ester spread; Assigned to Arm(s): Stanol ester | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo spread; Assigned to Arm(s): Placebo spread | Intervention Type: DIETARY_SUPPLEMENT; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean diet group
C: Arm Label: BALANCE group; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Arm Label: Control Diet group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control diet | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE group | Intervention Type: BEHAVIORAL; Name: Control diet; Assigned to Arm(s): Control Diet group
D: Arm Label: Mediterranean Diet Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet Intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet Intervention; Assigned to Arm(s): Mediterranean Diet Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 1) The Effect of Xenon and Sevoflurane on Hypnosis Monitors. 2) Prevention of Postoperative Nausea and Vomiting. 3) Rescue Treatment of Established Postoperative Nausea and Vomiting. Sevoflurane.
Brief Summary: The purpose of this study is ad 1) to measure the depth of hypnosis as assessed by BIS and cAAI during an average general anesthesia with xenon or sevoflurane and to establish a reliable monitoring system for measuring and documenting the actual depth of hypnosis for the volatile anesthetics investigated. Ad 2) the question is to be answered whether 4 mg dexamethasone i.v. is an effective prophylactic treatment against postoperative nausea and vomiting in case of xenon or sevoflurane anesthesia. Ad 3) it serves to gain evidence about the (non-)effectiveness and kinetics of ondansetron as antiemetic remedy after xenon or sevoflurane anesthesia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Ondansetron | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 6
B: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
C: Arm Label: Ondansetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: Granisetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granisetron | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Granisetron
D: Arm Label: Dexamethasone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous dexamethasone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Homologated placebo. | Intervention Type: DRUG; Name: intravenous dexamethasone; Assigned to Arm(s): Dexamethasone group | Intervention Type: DRUG; Name: Homologated placebo.; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People
Brief Summary: Despite formal recommendations, evidence of efficacy of aspirin in individuals with diabetes is scant and controversial. While the efficacy of aspirin versus placebo in patients with diabetes is currently under investigation in big randomized controlled trials, the putative additive effects of aspirin and statins in this population remain to be investigated. Moreover there are no data examining the pathophysiologic means by which aspirin with or without statins affects thrombosis in diabetic patients.

The aim of this trial is to evaluate the efficacy of low-dose aspirin (100 mg/daily), statins, both or neither for the reduction of thrombin generation. These preventive strategies will be evaluated on the top of the other strategies aimed at optimizing the care of diabetic patients in terms of metabolic control and control of the other cardiovascular risk factors.


Options:
A: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: Group 1: 0 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 2: 1.25 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 3: 2.5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 4: 5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 5: 10* g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 6: Placebo/Placebo (PBO/PBO); Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO) | Intervention Type: DRUG; Name: Goserelin acetate; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO)
C: Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People
Brief Summary: Despite formal recommendations, evidence of efficacy of aspirin in individuals with diabetes is scant and controversial. While the efficacy of aspirin versus placebo in patients with diabetes is currently under investigation in big randomized controlled trials, the putative additive effects of aspirin and statins in this population remain to be investigated. Moreover there are no data examining the pathophysiologic means by which aspirin with or without statins affects thrombosis in diabetic patients.

The aim of this trial is to evaluate the efficacy of low-dose aspirin (100 mg/daily), statins, both or neither for the reduction of thrombin generation. These preventive strategies will be evaluated on the top of the other strategies aimed at optimizing the care of diabetic patients in terms of metabolic control and control of the other cardiovascular risk factors.


Options:
A: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
C: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin
D: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study was designed to provide pivotal confirmation of efficacy and safety data for 2 doses of indacaterol (150 and 300 µg once daily \[od\]) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Data from this study will be used for the registration of indacaterol in Japan.


Options:
A: Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: olodaterol, Drug: tiotropium | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg capsules | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 300 μg capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Indacaterol 150 μg capsules; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Indacaterol 300 μg capsules; Assigned to Arm(s): Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 125mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo only | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: GSK573719 125mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GW642444 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo only; Assigned to Arm(s): Placebo

Answer: B